AdventHealth

 

Insights from 2023 ESMO Annual Meeting
Avatar

ESMO23 Highlights in Urothelial Carcinoma

By Insights from 2023 ESMO Annual Meeting FEATURING Guru Sonpavde, Bradley McGregor
By Insights from 2023 ESMO Annual Meeting FEATURING Guru Sonpavde, Bradley McGregor
0 views
November 28, 2023
Comments 0
Login to view comments. Click here to Login
Oncology
22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
20:41
2024 ASCO® Annual Meeting Insights Hub

Bladder Cancer Highlights From ASCO® 2024

Feat. G. Sonpavde
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
13:54
AdventHealth

FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advan…

Feat. G. Sonpavde
14:00
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…

Feat. G. Sonpavde
31:30
Insights from 2023 ESMO Annual Meeting

ESMO23 Highlights in Urothelial Carcinoma

Feat. G. Sonpavde, B. McGregor
22:19
Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Feat. G. Sonpavde
13:54
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Key Bladder Cancer/Urothelial Carcinoma Up…

Feat. G. Sonpavde
09:12
AdventHealth

Update on the FDA Accelerated Approval of Enfortumab Vedotin + Pembr…

Feat. G. Sonpavde
04:35
ESMO 2022 Conference Coverage

ESMO 2022 on the 4-Factor Model to Predict Response and Survival Ben…

Feat. G. Sonpavde
12:10
ESMO 2022 Conference Coverage

ESMO 2022: Key Bladder Cancer/Urothelial Carcinoma Presentations

Feat. G. Sonpavde
09:01
SABCS 2022 Conference Coverage

Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Ye…

Feat. W. Mchayleh